Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Healius Limited ( (AU:HLS) ) has shared an update.
Healius Limited has disclosed a change in the interests of non-executive director Katherine Ostin, reflecting the vesting of share rights into fully paid ordinary shares under the company’s non-executive director (NED) share plan. The transaction, effective 23 April 2026, converts previously issued share rights awarded in lieu of director fees into restricted ordinary shares, increasing Ostin’s overall equity exposure while involving no on-market trading or changes to contractual interests.
The update indicates that Ostin now holds a mix of direct and indirect ordinary shares and share rights through personal holdings, a family trust, and a nominee arrangement. This adjustment aligns director compensation more closely with shareholder outcomes by further linking board remuneration to the company’s share performance, without altering the company’s broader capital structure or signaling a change in strategic direction.
The most recent analyst rating on (AU:HLS) stock is a Sell with a A$0.77 price target. To see the full list of analyst forecasts on Healius Limited stock, see the AU:HLS Stock Forecast page.
More about Healius Limited
Healius Limited is an Australian healthcare company that operates in diagnostic services and related medical support. The group focuses on providing pathology, imaging, and day hospital services across Australia, supporting clinicians, hospitals, and patients through a national network of facilities and centres.
Average Trading Volume: 3,454,855
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$388.5M
See more insights into HLS stock on TipRanks’ Stock Analysis page.